Tibet Pharmaceutical announced that ACCUREDIT THERAPEUTICS US LIMITED, a subsidiary of the company's holding subsidiary, received a notice from the US FDA to agree to carry out planned clinical research on Art002G1 injection in the US. This drug is an in vivo gene-edited drug targeting PCSK9. The indications are adult heterozygous familial hypercholesterolemia and adult hypercholesterolemia with high/very high risk atherosclerotic cardiovascular disease. As of the announcement date, the drug had invested a total of 66.0316 million yuan in research and development. The product is currently in the early stages of research, and there is uncertainty about whether and when it will be approved for future marketing.

Tibet Pharmaceutical announced that ACCUREDIT THERAPEUTICS US LIMITED, a subsidiary of the company's holding subsidiary, received a notice from the US FDA to agree to carry out planned clinical research on Art002G1 injection in the US. This drug is an in vivo gene-edited drug targeting PCSK9. The indications are adult heterozygous familial hypercholesterolemia and adult hypercholesterolemia with high/very high risk atherosclerotic cardiovascular disease. As of the announcement date, the drug had invested a total of 66.0316 million yuan in research and development. The product is currently in the early stages of research, and there is uncertainty about whether and when it will be approved for future marketing.